Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. (Q45423758)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

oncolytic virus

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Samuel D Rabkin

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Varghese S

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Liu R

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Nielsen PG

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Ipe T

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Martuza RL

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 March 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Cancer Gene Therapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

253-265

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700900

0 references

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Novel therapeutic strategies for androgen-independent prostate cancer: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Conditionally replicating herpes vectors for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic herpes simplex virus vectors for cancer virotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Prostate cancer in a transgenic mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Antigen presentation by MHC class I and its regulation by interferon gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Correlation between major histocompatibility complex class I molecules and CD8+ T lymphocytes in prostate, and quantification of CD8 and interferon-gamma mRNA in prostate tissue specimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Genetics of natural resistance to herpesvirus infections in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Cytokines in cancer immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Interleukin-12 and the regulation of innate resistance and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Immune surveillance against a solid tumor fails because of immunological ignorance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Cancer as a robust system: implications for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of tumor evasion from the immune response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in immunotherapyfor prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased incidence of pathological and clinical prostate cancer with age: age related alterations of local immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-12 deaths: explanation and a puzzle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CGT.7700900

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45423758&oldid=1856257296"